TSE:AUP - Aurinia Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$8.30 +0.12 (+1.47 %) (As of 02/20/2019 04:00 PM ET)Previous CloseC$8.18Today's RangeC$8.05 - C$8.3352-Week RangeC$6.44 - C$10.47Volume38,708 shsAverage Volume90,935 shsMarket CapitalizationC$709.65 millionP/E Ratio-13.26Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada. Receive AUP News and Ratings via Email Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Technical & System Software Sub-IndustryN/A SectorComputer and Technology Current SymbolTSE:AUP Previous SymbolTSE:ISA CUSIPN/A Webwww.auriniapharma.com Phone+1-250-7084272Debt Debt-to-Equity RatioN/A Current Ratio20.93 Quick Ratio20.29Price-To-Earnings Trailing P/E Ratio-13.26 Forward P/E Ratio-10.25 P/E GrowthN/A Sales & Book Value Annual SalesC$466,000.00 Price / Sales1,522.86 Cash FlowC$1.63 per share Price / Cash Flow5.10 Book ValueC$1.47 per share Price / Book5.65Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees33 Outstanding Shares85,500,200Market CapC$709.65 million OptionableNot Optionable Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP." When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Aurinia Pharmaceuticals. Has Aurinia Pharmaceuticals been receiving favorable news coverage? News stories about AUP stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near future. Who are some of Aurinia Pharmaceuticals' key competitors? Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), Computer Modelling Group (CMG), Absolute Software (ABT), TECSYS (TCS), 99 Wuxian (NNW), iSentia Group (ISD), LeoNovus (LTV), Smart Parking (SPZ), Sensen Networks (SNS), NexJ Systems (NXJ), Western Resources (WRX), VIQ Solutions (VQS), Totally Hip Technologies (THP), Covata (CVT) and Labrador Technologies (LTX). Who are Aurinia Pharmaceuticals' key executives? Aurinia Pharmaceuticals' management team includes the folowing people: Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)Mr. Michael R. Martin, Co-Founder & COOMr. Dennis Bourgeault CPA, C.A., CFO & Sec.Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.Dr. Neil Solomons M.D., Chief Medical Officer How do I buy shares of Aurinia Pharmaceuticals? Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Aurinia Pharmaceuticals' stock price today? One share of AUP stock can currently be purchased for approximately C$8.30. How big of a company is Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has a market capitalization of C$709.65 million and generates C$466,000.00 in revenue each year. Aurinia Pharmaceuticals employs 33 workers across the globe. What is Aurinia Pharmaceuticals' official website? The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272. MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 184 (Vote Outperform)Underperform Votes: 119 (Vote Underperform)Total Votes: 303MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?